These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The roles of interleukin-5 and eotaxin in signal transmission between lung and bone marrow of rat asthmatic models].
    Author: Liu CT, Wang K, Li L, Pang YM.
    Journal: Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):558-62. PubMed ID: 17074272.
    Abstract:
    OBJECTIVE: To explore the roles of interleukin-5 (IL-5) and eotaxin in signal transmission between lung and bone marrow in rat asthmatic models and to investigate the effects of different interventions on the signal transmission. METHODS: Forty Wistar rats were randomly assigned to a control group and an asthma group (20 in each group). The asthmatic model were established by ovalbumin (OVA) sensitizing and challenging. The animals were sacrificed 30 min, 6 h, 12 h, 24 h, and 48 h after challenging, respectively. Slides were prepared from peripheral blood, bone marrow, and lung tissue respectively, and stained with HE. Then the total number and percentage of eosinophils (EOS) were counted. The concentrations of IL-5 and eotaxin in the lung homogenate at the different time points were determined by Enzyme-linked immunosorbent assay (ELISA). The bone marrow cells of the control rats and sensitized rats were incubated with lung homogenate of the different time points, and treated with dexamethasone (DXM), Galectin-3, anti-IL-5 polyclonal antibody, and montelukast, respectively. The bone marrow cell slides were stained with anti-IL-5 polyclonal antibody, anti-IL-5Ralpha polyclonal antibody, anti-eotaxin polyclonal antibody, anti-CD(34) polyclonal antibody, and anti-CCR(3) polyclonal antibody, respectively. The EOS and immunoactive cells were counted and represented as percentages of the total cells. RESULT: The percentages of EOS in peripheral blood, bone marrow, and lung tissue from the asthma group were 0.0200 +/- 0.0020, 0.023 +/- 0.003, 0.0250 +/- 0.0090, and those from the control group were 0.0100 +/- 0.0030, 0.009 +/- 0.003, 0.0090 +/- 0.0020 respectively. The differences were significant between the two groups (t = 2.547, 2.718, 2.718, all P < 0.05). The peak levels of IL-5 and eotaxin were (89.3 +/- 2.4) pg/ml at 6 h and (4.9 +/- 0.5) pg/ml at 12 h after allergy challenge, respectively, then the levels returned to the baseline value after 48 h (1.45 +/- 0.23) pg/ml. Except at 30 min, all other lung homogenate samples induced the increase of percentages of IL-5(+), IL-5Ralpha(+), eotaxin(+), CD(34)(+) and CCR(3)(+) immunoactive cells. After treatment with Galectin-3, the percentages of IL-5(+), IL-5Ralpha(+), eotaxin(+), CD(34)(+) and CCR(3)(+) immunoactive cells decreased to 0.021 +/- 0.005, 0.074 +/- 0.007, 0.138 +/- 0.014, 0.067 +/- 0.010, 0.040 +/- 0.005, 0.087 +/- 0.012. CONCLUSION: Galectin-3, a selective inhibitor of IL-5 mRNA transcription, potentially suppresses eosinophilic inflammation and might be a promising specific anti-asthma agent.
    [Abstract] [Full Text] [Related] [New Search]